S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
LON:DXRX

Diaceutics (DXRX) Share Price, News & Analysis

GBX 107
+3.00 (+2.88%)
(As of 03/28/2024 07:39 PM ET)
Today's Range
104
107
50-Day Range
90
107
52-Week Range
79
110
Volume
89,685 shs
Average Volume
53,858 shs
Market Capitalization
£90.61 million
P/E Ratio
10,500.00
Dividend Yield
N/A
Price Target
GBX 150

Diaceutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.2% Upside
GBX 150 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
£3.32 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.12 out of 5 stars

DXRX stock logo

About Diaceutics Stock (LON:DXRX)

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

DXRX Stock Price History

DXRX Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Diaceutics PLC (DXRX.L)
See More Headlines
Receive DXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Phone
N/A
Fax
N/A
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 150
High Stock Price Target
GBX 150
Low Stock Price Target
GBX 150
Potential Upside/Downside
+40.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£21.90 million
Cash Flow
GBX 34.30 per share
Book Value
GBX 49 per share

Miscellaneous

Free Float
N/A
Market Cap
£90.61 million
Optionable
Not Optionable
Beta
0.42
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Julie Browne
    Chief Operating Officer
  • Ms. Gillian Shaw
    General Counsel
  • Ms. Norma Thompson
    Global Head of Human Resources
  • Mr. Jordan Clark
    Chief Commercial Officer
  • Ms. Susanne Munksted
    Chief Precision Medicine Officer
  • Ms. Jillian Beggs
    Chief Commercial Officer
  • Ms. Marieke Hoefsmit
    Senior Director & Head of Data Delivery Netherlands
  • Ms. Bethany Slifko
    Head of Knowledge & Insight Team US
  • Ms. Sally Craig
    Company Secretary

DXRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Diaceutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diaceutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DXRX shares.
View DXRX analyst ratings
or view top-rated stocks.

What is Diaceutics' stock price target for 2024?

2 brokerages have issued 12-month target prices for Diaceutics' shares. Their DXRX share price targets range from GBX 150 to GBX 150. On average, they anticipate the company's share price to reach GBX 150 in the next year. This suggests a possible upside of 40.2% from the stock's current price.
View analysts price targets for DXRX
or view top-rated stocks among Wall Street analysts.

How have DXRX shares performed in 2024?

Diaceutics' stock was trading at GBX 87 at the beginning of 2024. Since then, DXRX shares have increased by 23.0% and is now trading at GBX 107.
View the best growth stocks for 2024 here
.

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:DXRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners